ACTG 265--SAFETY AND IMMUNOGENICITY OF LIVE ATTENUATED VARICELLA VACCINE

ACTG 265--水痘减毒活疫苗的安全性和免疫原性

• 批准号: 6120809
• 负责人: SANDRA BURCHETT
• 金额: $ 3.04万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6120809
• 关键词: HIV infections; attenuated microorganism; chickenpox; child (0-11); clinical research; clinical trial phase I; data collection; drug screening /evaluation; human subject; human therapy evaluation; immunity; immunotherapy; live vaccine; pediatric AIDS; viral vaccines

This study is a phase I/II pediatric ACTG trial of the safety and immunogenicity of live attenuated varicella vaccine in HIV-infected children with minimal immunodeficiency. The purpose is to examine the effects of a live-attenuated varicella vaccine on HIV-infected children. The primary questions to be answered concern the safety of the vaccine, when used within this patient population, and the extent to which these subjects are capable of mounting an immune response to the vaccine. Data from a comparison group of HIV-infected subjects with a history of wild type varicella, will be collected. The data will be used to examine whether the vaccine is capable of evoking immune responses similar to those mounted against the disease itself.

本研究是一项I/II期儿科ACTG安全性和安全性试验